Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin therapy in sarcoidosis
2013-005376-17Phase 2Terminated
- Sponsor
- Erasmus MC
- Start
- Feb 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in sarcoidosis, sponsored by Erasmus MC. Primary endpoint: Change in SRS uptake. Started Feb 2014; status: terminated.
02
Drugs
octreotide
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on 2013-005376-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005376-17.